BioNTech SE - ADR BNTX shares are trading lower by 12.6% at $364 Wednesday morning after findings from a recent Mayo Clinic study showed competitor Moderna's COVID-19 vaccine could possibly be more effective against the Delta variant.
Before the market open Wednesday, Bryan Garnier analyst Olga Smolentseva upgraded BioNTech Wednesday from Neutral to Buy and announced a $451 price target.
HC Wainwright & Co. analyst Robert Burns maintained BioNTech with a Neutral and raised the price target from $194 to $330.
BioNTech has a 52-week high of $464 and a 52-week low of $54.10.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
